For the indication in Schizophrenia, the CHMP assessed the proposed dosing, and was of the opinion that although the 8 mg dose could be considered as a treatment option for particular patients with schizophrenia, treating physicians should individualise treatment and use the lowest efficacious dose for each patient with a target dose of 4 to 6 mg/ day.
Skisofreenia näidustuse puhul hindas inimravimite komitee pakutud annustamist ning oli seisukohal, et kuigi 8 mg annust võib pidada konkreetsete skisofreenia diagnoosiga patsientide puhul ravivõimaluseks, peaksid raviarstid ravi patsiendile kohandama ja kasutama iga patsiendi puhul madalaimat tõhusat annust, kasutades sihtannusena 4– 6 mg/ päevas.